Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 4
1998 2
1999 1
2000 4
2001 3
2002 1
2003 4
2004 7
2005 6
2006 11
2007 6
2008 9
2009 11
2010 11
2011 17
2012 12
2013 9
2014 11
2015 7
2016 5
2017 3
2018 8
2019 7
2020 6
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
BACKGROUND: Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer. METHODS: We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or prima …
BACKGROUND: Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian can …
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Tewari KS, et al. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216226 Free PMC article. Clinical Trial.
PURPOSE: We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS: A total …
PURPOSE: We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial …
Primary peritoneal carcinoma: computed tomography and magnetic resonance findings.
Voultsinos V, Semelka RC, Elias J Jr, Altun E, Huertas C, Woosley JT, Balci NC. Voultsinos V, et al. J Comput Assist Tomogr. 2008 Jul-Aug;32(4):541-7. doi: 10.1097/RCT.0b013e318133a9d8. J Comput Assist Tomogr. 2008. PMID: 18664839
OBJECTIVE: To present computed tomography (CT) and magnetic resonance imaging (MRI) findings of primary peritoneal carcinoma (PPC) at initial presentation (IP) and recurrent disease (RD). ...
OBJECTIVE: To present computed tomography (CT) and magnetic resonance imaging (MRI) findings of primary peritoneal carcinom …
Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma.
Connolly CF, Yahya S, Chan KK, Singh K, Sundar S, Anwar SM, Fernando I. Connolly CF, et al. Anticancer Res. 2016 Jan;36(1):255-9. Anticancer Res. 2016. PMID: 26722051
AIM: Primary peritoneal carcinoma (PPC) has a poor prognosis, with a median survival of 11-24 months. ...IDS in selected cases of PPC appears to improve median OS and PFS in PPC and we would recommend that surgery is considered as a treatment option in all pa …
AIM: Primary peritoneal carcinoma (PPC) has a poor prognosis, with a median survival of 11-24 months. ...IDS in selecte …
Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.
Zhang C, Li XP, Cui H, Shen DH, Wei LH. Zhang C, et al. J Zhejiang Univ Sci B. 2008 Jun;9(6):435-40. doi: 10.1631/jzus.B0820051. J Zhejiang Univ Sci B. 2008. PMID: 18543395 Free PMC article.
OBJECTIVE: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). METHODS: Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. ...
OBJECTIVE: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). ME …
Emerging therapeutics for primary peritoneal cancer.
Slomovitz BM, Worley MJ, Markman M, Coleman RL. Slomovitz BM, et al. Expert Opin Emerg Drugs. 2011 Mar;16(1):71-84. doi: 10.1517/14728214.2011.526600. Expert Opin Emerg Drugs. 2011. PMID: 21352070 Review.
AREAS COVERED: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trials website (http://www.Clinicaltrials.gov). We also reviewed abstracts presented at recent oncology congresses, such as the 2010 Annual meeti …
AREAS COVERED: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trial …
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
Fukuda T, Imai K, Yamauchi M, Teramae M, Hashiguchi Y, Ichimura T, Yasui T, Sumi T. Fukuda T, et al. Eur J Gynaecol Oncol. 2015;36(1):49-53. Eur J Gynaecol Oncol. 2015. PMID: 25872334
PURPOSE OF INVESTIGATION: Primary peritoneal carcinoma (PPC) is histologically similar to ovarian serous carcinoma, but its biochemical features remain obscure. The authors investigated and compared clinical findings, treatments, and outcomes of patien …
PURPOSE OF INVESTIGATION: Primary peritoneal carcinoma (PPC) is histologically similar to ovarian serous carcinoma, but …
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Auer RC, et al. Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24. Eur J Cancer. 2020. PMID: 31986452
There is insufficient evidence to recommend the addition of HIPEC when primary CRS is performed for patients with newly diagnosed, primary advanced epithelial ovarian, fallopian tube or primary peritoneal carcinoma or in those with recurrent ovarian cancer ou …
There is insufficient evidence to recommend the addition of HIPEC when primary CRS is performed for patients with newly diagnosed, primary a …
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, Cassani C, Tognon G, Tamberi S, Mangili G, Mammoliti S, De Giorgi U, Greco F, Mosconi AM, Breda E, Artioli G, Andreetta C, Casanova C, Ceccherini R, Frassoldati A, Salutari V, Giolitto S, Scambia G. Lorusso D, et al. J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315944 Clinical Trial.
PURPOSE: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype. METHODS: A prospective, open-label, randomized phase III MITO-23 trial evaluated the ac …
PURPOSE: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BR …
149 results